department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Zelboraf · pharmadog

pharmadog
drugs
Zelboraf

drug · small molecule

patient view →

vemurafenib

Marketedupdated 2mo ago

by F. Hoffmann-La Roche Ltd🔗 ChEMBL

Approved

community read0 votes

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 13 investigational indications.

indications

investigational

NSCLC

targets

Serine/threonine-protein kinase B-raf

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Zelboraf

trade names

Zelboraf

generic

vemurafenib

MOA

Serine/threonine-protein kinase B-raf inhibitor

indication

Hairy Cell Leukemia

phase

marketed

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed just now

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

Patent cliff

source: FDA Orange Book

first barrier falls

Aug 2, 2026

26 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (6)

Jun 6, 2032formulationUS 9447089
Jul 27, 2030compositionUS 87419204.1y
Jun 20, 2029compositionUS 78632883.0y
Oct 22, 2026compositionUS 7504509107d
Aug 2, 2026method-of-use (U-1418)US 847081826d
Jun 21, 2026compositionUS 8143271

Trials studying vemurafenib

phase2A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)recruitingn=99
phase2TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancerrecruitingn=4,200
phase1Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgerycompletedn=47
phase2Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Canceractive not recruitingn=24
phase2A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)recruitingn=86
phase2Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancercompletedn=10
phase2Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)recruitingn=720
phase3A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)active not recruitingn=1,000

more trials →